ITMCTR1900002445
Recruiting
Phase 1
TCM syndrome study of psoriasis vulgaris based on intestinal microflora
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University0 sitesTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnostic criteria for psoriasis vulgaris.
- •2\. Conforming to the syndrome differentiation standard of TCM syndrome differentiation which was diagnosed by at least two deputy chief physicians or above.
- •3\. Aged 18 to 65 years.
- •4\. The patients and health controls are as consistent as possible in their living and eating habits.
- •5\. Volunteer to participate in the case registration study and sign the informed consent.
Exclusion Criteria
- •1 Body mass index is greater than or equal to 35 or less than or equal to 18\.
- •2 The following drugs have been used in the past 6 months: antibiotics, antifungal, antiviral or antiparasitic drugs; cortisol drugs, cytokines, methotrexate Or immunosuppressive agents which were given orally / injected intravenously / injected intravenously or inhaled.
- •3 Oral administration of large doses of probiotics, contraceptive,or alcohol in the past 15 days.
- •4 Vaccinated with a virus vaccine in the past 28 days.
- •5 In a relatively serious disease state during the sampling period.
- •6 Patients with an immunodeficiency disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
CT 327 in the treatment of psoriasis vulgaris: A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for Eight Weeks to Patients with Mild to Moderate Psoriasis Vulgaris - CT 327 in the treatment of psoriasis vulgarisPsoriasis VulgarisEUCTR2010-021207-25-GBCreabilis Sàrl36
Unknown
Phase 3
M518101 phase III study in plaque psoriasis patientsPlaque psoriasisJPRN-jRCT2080222894Maruho Co.,Ltd.
Not yet recruiting
Phase 2
Clinical Study Of unani formulation and betamethsone in the treatment of Psoriasis.Health Condition 1: L409- Psoriasis, unspecifiedCTRI/2020/07/026420central counsal for research in unani medicine new delhi
Recruiting
Not Applicable
The Vitamin D and Psoriasis StudyPsoriasis vulgarisSkin - Dermatological conditionsDiet and Nutrition - Other diet and nutrition disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12611000648921Massey University100
Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 2Plaque psoriasisJPRN-jRCT2080221434Maruho Co.,Ltd.